Drug Approval | December 18, 2025
FDA nod to Johnson & Johnson’s AKEEGA for aggressive prostate cancer
Patients with BRCA mutations often face aggressive disease and poor prognosis
Patients with BRCA mutations often face aggressive disease and poor prognosis
The ChemiSphere app exemplifies how M-Trust technology transforms workflows into seamless digital experiences
Bertozzi currently serves as the Baker Family Director of Sarafan ChEM-H, Anne T. and Robert M. Bass Professor at Stanford University, and Investigator of the Howard Hughes Medical Institute
The company shall process the change of name application with BSE Ltd. in due course
Convenient subcutaneous option has potential to reach more patients with same clinical benefits as Saphnelo IV infusion
The pharmaceutical giant now expects 2026 revenues to land between $59.5 billion and $62.5 billion
The company operates a chain of mid-sized multi-speciality hospitals
The randomized, double-blind, placebo-controlled single ascending dose (SAD) study evaluated safety, tolerability, pharmacokinetics, and target engagement in 46 healthy participants
The reform is set to modernise how medicines are developed, authorised, and made available across the EU
Subscribe To Our Newsletter & Stay Updated
